Research · Sep 3, 2026
[WAY] Waystar Holding Thesis 2026: A Healthcare-Payments and AI-Revenue-Cycle Compounder Rides Provider-Software Adoption
Waystar Holding Corp. (NASDAQ: WAY), headquartered in Lehi, Utah (corporate HQ + Salt-Lake-City-and-Provo-Utah) and Atlanta, Georgia (operational HQ + Atlanta-GA-Waystar-Navicure), is a healthcare-payments + emerging-AI-revenue-cycle-management SaaS post-2024-NYSE-IPO platform providing distinctive multi-cycle Waystar-Hubble-AI + emerging-AI-revenue-cycle-management services to US-Provider + Hospital + Health-System + Group-Practice + emerging-multi-jurisdiction customer base. Founded 2018 as Waystar (combining Navicure 1995-founding + ZirMed 1999-founding under Bain Capital + EQT Group + Canada Pension Plan Investment Board CPPIB PE-controlling ownership); 2019 Recondo Technology acquisition + 2021 eSolutions acquisition + 2024 Patientco acquisition; June 2024 substantial NYSE IPO. Multi-decade strategic-evolution: 2018-2024 private-stage Waystar + Navicure + ZirMed + Recondo + eSolutions + Patientco platform; June 2024 NYSE IPO providing public-equity capital + deleveraging; 2024-2025 post-IPO Waystar + Hubble-AI + emerging-AI-revenue-cycle-management + Provider-software adoption + deleveraging-post-IPO + Matt-Hawkins-strategic-execution. Under founder-CEO Matt Hawkins (since 2018, ~8+ year founder-and-CEO + Sunquest Information Systems + Waystar-Navicure + ZirMed expertise), FY2025 closes with selected various aggregate revenue ~$1.05-1.20B, adj. EBITDA ~$430-510M, adj. EPS ~$0.85-1.35, net debt ~$0.9-1.2B, and ~170M shares outstanding. The first deep-dive — Healthcare-Payments + AI-Revenue-Cycle-Management Waystar-Hubble-AI franchise — covers entire healthcare-payments + AI-revenue-cycle-management SaaS business + Waystar-and-Hubble-AI positioning. Platform: Waystar-revenue-cycle-management + Waystar-Hubble-AI + emerging-AI-revenue-cycle-management. Revenue mix: Subscription ~80-85% (Waystar-subscription + Waystar-revenue-cycle-management + Hubble-AI), Volume-and-Implementation ~15-20%. Product portfolio: Patient-Financial-Experience + Claims-Management + Provider-Eligibility-and-Verification + Authorizations + Denials-and-Appeal + Patient-Estimates + Patient-Payments + Waystar-Hubble-AI. Customer base: ~30K+ Provider/Hospital/Health-System clients. ~5-10% US-healthcare-payments + revenue-cycle-management category-share. Competes with R1 RCM (private + TowerBrook-and-Coatue-2024-acquired most-direct-larger-RCM-comp), Change Healthcare (UnitedHealth-Group-Optum-acquired 2022 most-direct-Change-Healthcare-Optum-comp), Optum (UNH most-direct-larger-Optum-comp), Cotiviti (private + Veritas-Capital most-direct-Cotiviti-comp), Health Catalyst (HCAT), Zelis (private + Bain-Capital-2024 most-direct-Zelis-comp), Veradigm (MDRX), HealthStream (HSTM), Phreesia (PHR most-direct-Patient-Engagement-comp), Definitive Healthcare (DH), Evolent Health (EVH most-direct-Value-Based-Care-comp), Multiplan (MPLN), athenahealth (private Bain-and-Hellman-Friedman), Epic Systems (private dominant-EHR), Oracle Health (Cerner Oracle-acquired 2022), MEDITECH (private), Surescripts (private), Olive AI (private), Notable Health (private). The second deep-dive — Matt-Hawkins + 2024-NYSE-IPO + Provider-software-and-AI compounder thesis — covers Matt-Hawkins-founder-CEO + ~8+ year founding-CEO + Sunquest Information Systems + Waystar-Navicure + ZirMed expertise, June-2024-NYSE-IPO transformational-platform + Bain-Capital-and-EQT-Group-and-CPPIB + multi-cycle-deleveraging-post-NYSE-IPO, emerging-Provider-software + emerging-AI-revenue-cycle-management + emerging-Hubble-AI structural-tailwinds. Multi-decade compounder thesis combines Waystar-and-Navicure-and-ZirMed + 2024-NYSE-IPO + Bain-Capital-and-EQT-Group-and-CPPIB ~30+ year heritage, ~30K+ Provider/Hospital/Health-System clients + ~5-10% category-share + Waystar-Hubble-AI platform, Matt Hawkins founder-CEO + Sunquest + Navicure + ZirMed expertise, multi-cycle-deleveraging + emerging-strategic-acquisition-target potential, emerging-Provider-software + AI-revenue-cycle-management + Hubble-AI structural-tailwinds. Capital position is post-NYSE-IPO, emerging-deleveraging, growth-and-Hubble-AI-focused, conservative: net debt ~$0.9-1.2B (~2.0-2.7x leverage post-2024-NYSE-IPO deleveraging), BB+/BBB-equivalent (emerging-IG), $0.15-0.30B cash + undrawn revolver liquidity, FCF emerging-modestly-positive, no dividend, no buyback, ~170M shares post-2024-NYSE-IPO + Bain-Capital-and-EQT-Group-and-CPPIB-PE-controlling. At ~$30-50 per share, equity value ~$5.1-8.5B, EV ~$6.0-9.7B, ~22-58x EPS and ~12-22x EV/EBITDA. Base case: Provider-software adoption + Waystar-Hubble-AI + AI-revenue-cycle-management + revenue $1.15-1.35B + adj. EBITDA $480-580M + adj. EPS $1.05-1.65 + deleveraging + ~10-25% return. Bull case: Provider-software adoption accelerates + emerging-Waystar-Hubble-AI + AI-revenue-cycle-management inflects + emerging-strategic-acquisition-target (R1-RCM + Optum + pharma-acquirer interest) + revenue $1.25-1.50B + adj. EBITDA $540-680M + adj. EPS $1.40-2.20 + re-rate 30-50x + 35-75%+ return + takeout-premium-upside. Bear case: Provider-software adoption disappoints + Waystar-Hubble-AI disappoints + AI-revenue-cycle-management disappoints + adj. EPS $0.40-0.65 + de-rate 18-25x + flat-to-substantially-negative.